Incyte Genomics Inc (INCY) Financial Statements
Historical financial data — 38 statements covering FY2016–FY2025
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with N...
Incyte Genomics Inc's revenue increased 21.2% year over year, from $4.24B to $5.14B.
Net income increased 3845.0% over the same period, from $32.6M to $1.29B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 365% in total.
Operating cash flow grew 321.5% to $1.41B.
Incyte Genomics Inc maintains a strong net profit margin of 25.0%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $1.76B+118.0% | $225.3M | $1.64B | $218.6M | $200.9M | $6.21B | N/A | $4.74B |
| Q3 FY2023 | $2.68B+52.1% | $396.5M | $2.50B | $433.3M | $348.8M | $6.39B | N/A | $4.93B |
| Q1 FY2024 | $880.9M-67.2% | $169.5M | $819.9M | $91.9M | $218.8M | $7.14B | N/A | $5.39B |
| Q3 FY2024 | $3.06B+247.7% | $-168.6M | $2.84B | $-240.1M | $-45.9M | $5.01B | N/A | $3.17B |
| Q1 FY2025 | $1.05B-65.6% | $158.2M | $979.7M | $205.2M | $266.1M | $5.75B | N/A | $3.67B |
| Q2 FY2025 | $2.27B+115.4% | $563.2M | $2.12B | $735.5M | $310.8M | $5.82B | N/A | $4.17B |
| Q3 FY2025 | $3.63B+60.2% | $987.4M | $3.38B | $1.18B | $870.2M | $6.33B | N/A | $4.65B |
| Q1 FY2026 | $1.27B-65.0% | $303.3M | $1.17B | $301.1M | $369.4M | $7.34B | N/A | $5.62B |
Balance Sheet Summary (Latest Period)
Total Assets
$6.96B
Total Liabilities
$1.79B
Total Equity
$5.17B
Cash & Equivalents
$3.10B
Total Debt
N/A
Current Assets
$5.02B
Current Liabilities
$1.52B
Retained Earnings
$213.8M